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Parkinson’s Disease was first introduced by James Parkinson in 
1817. Since then, major strides have been made in the 
development of its treatment. Early treatments were dominated 
by traditional and complementary therapies, which were largely 
serendipitous and observation-based. Current drug-based 
therapies manifest in the form of levodopa accompanied by 
dopamine agonist, COMT inhibitor, or MAO-B inhibitor, for the 
purpose of reducing the levodopa-induced symptom fluctuation. 
In terms of surgical treatment, while ablative surgeries in the 
brain have been abandoned due to high mortality rate in the 
late 1900s, Deep Brain Stimulation in the subthalamic nucleus or 
internal globus pallidus has mostly replaced ablative surgeries 
since its introduction in 1987. Current research topics include 
non-dopaminergic agents for motor fluctuation reduction, 
transplantation of dopaminergic neurons, gene therapies using 
viral vectors, reduction of alpha-synuclein neurotoxicity, and 
neuroprotective therapies. Especially, due to the fact that the 
etiology of the disease is yet to be elucidated, neuroprotective 
therapies aimed at slowing or stopping disease progression are of 
particular interest. It is suggested that future research should 
aim towards clarifying the cause of the disease, for the 
development of a treatment that can permanently halt or reverse 
Parkinson’s Disease-related neurodegeneration. 
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Introduction 
 
Parkinson’s Disease (PD) is a neurodegenerative disease characterized by 
distinct triad cardinal motor symptoms of bradykinesia, rigidity, and resting 
tremor. It is caused by dopamine deficiency following the loss of dopaminergic 
neurons primarily in the substantia nigra pars compacta (SNc), but the reason 
for the neuronal death is unknown to date. However, it is strongly suggested 
that, in cases of idiopathic PD, the combination of genetic factors and 
environmental factors leads to various mechanisms that trigger neuronal death 
[1]. It is often accompanied by the pathological hallmark of Lewy Bodies - 
aggregated alpha-synuclein proteins - in the nigrostriatal pathway.  
Since its first medical introduction by James Parkinson in 1817 [2], there have 
been major strides in the development of treatments for PD, from 
anticholinergics and ablative surgeries to levodopa to Deep Brain Stimulation. 
Current research revolves around developing therapies that can stop or reverse 
the progression of the disease. A number of agents are being tested for their 
neuroprotective abilities, but none of them have been proven adequate for clinical 
use to date [3]. Although all current therapies are symptomatic in nature and no 
single cure for the disease exists, the development of new molecular targets, 
biomarkers, and toxin animal models are providing a deeper understanding of the 
causes and mechanisms of PD. This article is a narrative of the major advances 
in the treatment for Parkinson’s Disease since its first description, as well as its 





Early treatments of PD were largely serendipitous and observation-based in 
nature, with traditional and complementary therapies prevailing.  
Although Parkinson acknowledged in his “An Essay on the Shaking Palsy” 
that a “countervailing remedy” is yet to be discovered, he hoped to find an 
intervention that would stop the progression of the disease [2]. Assuming that the 
disease originates from the medulla, he recommended venesection in the upper 
part of the neck, followed by the insertion of vesicatories to induce inflammation 
on the skin; this was intended to divert blood away from the medulla and 
depressurize it [2].  
Early pharmacological treatments were dominated by anticholinergics, which 
reduce the acetylcholine levels in the central nervous system to restore the 
acetylcholine-dopamine balance in PD patients. The first widely-recognized 
groups of drugs were belladonna alkaloids, first introduced by Charcot’s student 
Ordenstein [4]. Out of multiple belladonna-based anticholinergic agents, Charcot 
especially advocated the use of hyoscyamine, along with rye-based ergot products 
from which today’s dopamine agonists are derived [5]. However, despite the 
widespread use of belladonna alkaloids, it was recognized by contemporary 
medical practitioners that they had moderate yet limited palliative effect on 
Parkinsonism [6]. 
Ablative surgeries in the brain were introduced in the early 1900s, with the 
development of a stereotaxic equipment by Horsley and Clarke [7]. In the 1940s, 
the basal ganglia was first targeted by Meyers for the reduction of Parkinsonian 
tremor, and noticed an improvement in rigidity as well as tremor; however, it 
was abandoned due to high mortality rates [8]. After Cooper’s serendipitous 
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discovery of the effect of thalamotomy on tremor in the 1950s [9], the procedure 
was used intermittently, but was also soon replaced by medication with the 









Following the discovery of dopamine deficiency in the striatum and the SNc of 
PD patients in 1960 by Ehringer and Hornykiewicz, levodopa, also known as l-
dopa, was proven effective as an anti-parkinsonian agent in 1961 [10]. Since then, 
levodopa still remains as the most effective therapy for controlling the motor 
symptoms of PD [11].  
As a precursor of dopamine, levodopa can cross the BBB, which in turn gets 
converted into dopamine in the brain, binds to D1 and D2 receptors, and restores 
dopamine deficit. However, most of the drug undergoes peripheral metabolism by 
amino acid-decarboxylase (AADC) and catechol-o-methyltransferase (COMT) 
before reaching the CNS, increasing the concentration of plasma dopamine and 
causing complications including nausea, vomiting, and orthostatic hypotension 
[8]. It is thus often taken together with AADC inhibitors such as carbidopa and 
benserazide, with the first combination of carbidopa-levodopa becoming 
commercially available in 1975 [12]. 
In addition to the side-effects, long-term use of levodopa inevitably leads to 
levodopa-induced fluctuation between the ‘on’ and ‘off’ periods: during ‘on’ 
periods, PD patients show a good response to the drug; during ‘off’ periods, 
motor complications, most often dyskinesia, predominate [13]. For this reason, 
levodopa treatment has often been delayed until significant impairment of 
function; however, increasing evidence suggests that delaying levodopa treatment 
has little impact in long-term motor symptoms, but only prevents patients from 
receiving therapeutic relief in the initial stages [14].  
As an alternative to oral administration of levodopa - which results in a 
discontinuous supply of levodopa to the brain and thus causes motor 
complications [15] - continuous levodopa-carbidopa intestinal gel infusion (LCIG) 
has been developed. In LCIG, levodopa-carbidopa can be infused through a 
percutaneous gastrojejunostomy tube by a battery-powered pump. Typical 
indications of LCIG are advanced PD complicated by “Off” periods that cannot 
be satisfactorily controlled with “optimized” medical therapy, where “optimized” is 
defined as a combination of levodopa-carbidopa, a dopamine agonist, and at least 
one other anti-parkinsonian agents (COMT inhibitor, MAO-B inhibitor) [16]. It 
is reported that LCIG results in a significant reduction of daily mean ‘off’ time 
and an increase of mean ‘on’ time without dyskinesia in advanced PD patients 
[16]; however, it is commonly accompanied by complications such as abdominal 
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Dopamine agonists 
 
Dopamine agonists (DA) are agents that bind to dopamine receptors to mimic 
the effects of dopamine. They have advantages over levodopa, in that they do not 
generate toxic metabolites, are independent of neuronal capacities, have longer 
half-lives than levodopa, and can target specific subtypes of dopamine 
receptors[18]. However, they are relatively less effective in terms of controlling 
motor symptoms than levodopa; for this reason, they are typically used in 
managing early stages or young onsets of PD, or as an adjunct to levodopa to 
reduce its “off” periods as well as dyskinesia [11]. 
Although they have less motor complications, DAs are associated with other 
side effects such as somnolence, edema, and hallucination [19]; moreover, the 
long-term perceived quality of life for PD patients treated with either DA or 
levodopa did not significantly differ [20]. Today, whether the monotherapy of DA 
followed by levodopa or the use of low initial dose of levodopa along with DAs is 
more effective in the long-term is yet to be concluded [11]. Common DAs in use 
include bromocriptine (Parlodel), pergolide (Permax), pramipexole (Mirapex), 
ropinirole (Requip), piribedil, cabergoline, apomorphine, and lisuride. 
In the 1980s, a novel way of apomorphine administration - continuous 
subcutaneous apomorphine infusion (CSAI) - was introduced, which injected the 
drug through a portable pump around the waist or the neck. The main indication 
for CASI is severe PD with pronounced motor fluctuations, dyskinesias, and 
nocturnal akinesia [21]. It was found to be more effective in reducing ‘off’ periods 
and dyskinesia than its oral counterpart [22]. However, one of the most common 
complications of CSAI, affecting approximately 50% of CSAI-treated PD 
patients, is the development of skin nodules at the injection sites; they can be 





In addition to inhibitors of AADC, inhibitors of COMT - an enzyme 
responsible for the peripheral metabolism of levodopa - have been used as a 
complement to levodopa to increase its elimination half-life and thus the duration 
of ‘on’ periods in PD patients [24]. 
COMT inhibitors have been associated with side effects such as nausea, 
vomiting, and mild dyskinesia due to increased dopaminergic stimulation, but 
most complications are mild [25]; nevertheless, tolcapone - a type of COMT 
inhibitor - has been associated with the risk of fulminant liver failure, while its 
counterpart entacapone does not show hepatotoxicity [26]. For this reason, 
tolcapone has been removed from European and Canadian market [27]. 
Recently, it has been suggested that the combined use of COMT inhibitors 
with levodopa does not have benefits over using levodopa alone: in a double-blind 
trial of 747 PD patients, those who received entacapone with levodopa in fact 




In 1983, Langston identified 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP)-derived Parkinsonism; MPTP, as a neurotoxin, is oxidized by 
monoamine oxidase-B (MAO-B) into MPP+, which is a toxic metabolite that 
kills dopaminergic neurons in the SNc [29]. MAO-B inhibitors - namely 
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selegiline(deprenyl) and rasagiline - were one of the first agents tested for their 
neuroprotective effects. In the 1989 clinical trial ‘Deprenyl and Tocopherol 
Antioxidative Therapy of Parkinsonism’ (DATATOP), selegiline was found to be 
able to significantly delay the time at which disease progression reached the stage 
that requires levodopa therapy; nonetheless, it was reported that whether the 
effects of selegiline were symptomatic or truly neuroprotective is unclear [30]. 
Similarly, in a 2005 clinical trial, rasagiline was demonstrated to be effective 
as a supplementary treatment to levodopa; it increased the duration of “on” time 
without dyskinetic side effects and the overall perceived quality of life, with 
dopaminergic side effects similar to those of the placebo group [31]. The potential 
neuroprotective function of rasagiline has been largely attributed to its ability to 
reduce the release of cytochrome C by closing the mitochondrial transition pore, 
modify pro-antiapoptotic genes and proteins, and inhibit the nuclear 
translocation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [32]. 
Nonetheless, the US Food and Drug Administration (FDA) concluded in 2011 
that there is insufficient evidence that supports the potential neuroprotective 
effects of rasagiline in PD [33]. 
 
 
Revival of surgeries 
 
In the late 1980s, ablative therapies, which were largely abandoned since the 
advent of levodopa in 1960, began to receive renewed attention. This was largely 
due to the limited efficacy of levodopa stemming from its motor complications 
and fluctuations, new understanding that the hyperactivity of subthalamic 
nucleus(STN) and internal globus pallidus (GPi) in PD could be controlled by 
STN lesions from MPTP primate models [34], and the development of novel 
neuroimaging techniques such as CT and MR [11]. 
After the report that the GPi is hyperactive in non-human primate models of 
PD [35], pallidotomy creating lesions in the GPi has received attention as an 
option for treating advanced PD patients. Unilateral pallidotomy was found to 
improve tremor, rigidity, bradykinesia, gait, and balance in 36 PD patients 
compared to those treated with medical therapy, and the effect was sustained 2 
years after the intervention [36]. A review article reported that the risk of adverse 
events following unilateral pallidotomy was about 30% with the most frequent 
being speech problem and facial paresis, and the mortality rate was 1.2% [37].  
Alternatively, subthalamotomy - which targets the STN - was found to 
improve parkinsonism in MPTP primate models [38]; however, in another study, 
unilateral subthalamotomy resulted in 16% of the subjects developing permanent 
dyskinesia as well as hemiballism and hemichorea [39]. 
Due to high risks of developing surgical complications following invasive 
ablative surgeries, thalamotomy, pallidotomy, and subthalamotomy have been 
mostly replaced by Deep Brain Stimulation in most countries. 
 
 
Deep brain stimulation 
 
DBS was first introduced by Benabid and colleagues as a less destructive 
alternative to lesioning procedures in 1987 [40]. It is the implantation of a 
continuous electrical stimulation device, which sends impulses to the STN or GPi 
to mitigate PD-related motor symptoms and dyskinesia [41] Neuronal 
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degeneration in the substantia nigra and the following  dopamine deficiency lead 
to an excessive excitation of GPi by the STN; the resulting inhibition of the 
thalamus reduces thalamocortical activity, which mediates various motor 
symptoms of PD. DBS is said to interfere with this pathophysiologic pathway, 
but the exact mechanism of action is unknown to date. Proposed mechanisms of 
DBS include the inhibition of neurons near the electrode to manage the output 
pathway, effect on the neurochemical state of the CNS, the disruption of PD-
related pathological oscillations, and the induction of synaptic plasticity [42]. 
DBS has advantages over ablative therapies as it is reversible without 
destroying the brain tissue, and over continuous infusions as no lines, needles, or 
portable pumps are necessary. The effectiveness of DBS has been demonstrated 
in a study in which advanced PD patients experienced an increase of 4.6 hours a 
day of ‘on’ period, 71% rise in motor improvement, and increased quality of life 
[43]. Its beneficial effect is known to persist for at least 3 to 5 years after DBS 
[44]. 
No significant difference between DBS in the STN and GPi has been reported 
in both the motor function and quality of life; although patients treated with 
STN DBS required less dopaminergic medications and had a greater decrease in 
visuomotor speed, there was no significant disparity in the occurrence of long-
term adverse events between patients treated with STN DBS and those treated 
with GPi stimulation [45]. 
Despite the absence of major lesions, DBS has been associated with significant 
surgical complications including infection, hemorrhage, seizure, pulmonary 
embolism, cerebrospinal fluid (CSF) leak, confusion or disorientation, and death 
[46]. DBS requires chronic implantation of electrodes and pulse generators, from 
which hardware complications frequently occur. In a review of 360 PD patients 
who received DBS therapy, complications of lead replacement or repositioning 
(due to fracture, malfunction, or dislocation), extension wire replacement, pulse 
generator replacement, and allergic reactions have been identified [46]. Although 
cognitive or behavioral complications related to electric stimulation have been 
relatively mild, it is suggested that DBS in the STN may be associated with the 
development of apathy [47]. Such condition is hypothesized to be triggered by a 
sudden postsurgical decrease in dopaminergic medication, and may be mitigated 
by an increased dosing of drugs [48]. Other potential complications include an 
increase in suicidal rate [49] and exacerbation of restless legs syndrome [50]. 
Current studies focus on increasing the precision and efficacy of DBS; for 
instance, there is mounting interest in the development of a closed-loop DBS, 
where stimulation can be turned on and off based on the presence of an increased 
oscillatory activity in PD patients [51]. The notion of increasing the anatomical 
specificity and adaptability of non-invasive DBS, such as transcranial magnetic 
stimulation and focused ultrasound, is also gaining interest [52].  
It is believed that a better understanding of the mechanisms involved in the 
reduction of PD motor symptoms via DBS will open up new applications and 
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Figure 1: Algorithm for the choice of medical and device-assisted treatment for PD. Originally based on the study 
of Dietrichs and Odin [53], with modifications made by the author. (PD: Parkinson’s Disease; MAO-Bi: MAO-B 
inhibitors; COMTi: COMT inhibitors; DBS: Deep Brain Stimulation; LCIG: Continuous levodopa-carbidopa 




 Rehabilitation is considered an adjunct to pharmacological and surgical 
therapies, in order to maximize functional ability. Although exercise cannot slow 
the progression of motor dysfunctions, it can improve functions in certain motor 
tasks[54] and alleviate a few nonmotor symptoms[55]. Regular physical exercise 
programs and physiotherapy may improve rigidity, hypokinesia, flexibility, gait, 
strength, and quality of life[56]. Lee Silverman Voice Treatment (LSVT), which 
aims to maximize vocal loudness, has been found to be effective for patients with 
dysarthria and hypophonia[57]. Occupational therapy often accompanies 
physiotherapy, and is found to improve self-perceived performance of daily 







Despite the remarkable effect of medicinal therapies, PD patients experience 
severe motor complications and fluctuations that significantly harm their quality 
of life. Thus, the use of non-dopaminergic agents for symptomatic relief has been 
extensively investigated.  
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Glutamate antagonists 
 
N-Methyl-d-aspartate (NMDA) glutamate receptors can be inhibited by 
glutamate antagonists such as amantadine and memantine, which can 
theoretically reduce the GABAergic inhibition of the thalamus and thus reduce 
motor symptoms. Amantadine has been shown to have antidyskinetic effects in 
PD patients [59], sustained for at least a year following the intervention [60]. 
Nonetheless, the development of psychiatric side effects has limited the use of 
glutamate antagonists in clinical settings [61]. 
Riluzole has also been shown to reduce dyskinesia with better patient 
toleration [62] and have neuroprotective effects on dopaminergic neuron in MPTP 
primate models [63], but in a 2002 clinical trial no significant change in Unified 
Parkinson Disease Rating Scale (UPDRS) motor score was observed [64]. 
 
Adenosine A2A antagonist 
 
Antagonists that target adenosine A2A receptors in striatal cholinergic 
interneurons, namely istradefylline, have been reported to significantly reduce the 
“off” time in PD patients [65]. Further investigation of adenosine A2A antagonists 
is being delayed, with the absence of approval from the US FDA [66].  
Other non-dopaminergic agents under investigation include: opioid 
antagonists, serotoninergic 5-HT2C agonists, cannabinoid CB1 agonists, ɑ2-
antagonists, dopamine uptake inhibitors, selective muscarinic antagonists, and 
nicotinic agonists [8]. However, most drugs have failed to be translated from 







For more than 2 decades, there has been a continuous effort to develop a 
therapy based on the restoration of dopaminergic neurons. The transplantation of 
fetal-derived mesencephalic dopaminergic cells showed some promising results 
with motor symptoms improving in younger patients; however, the majority of 
the patients developed “off” period dyskinesia that persisted even after medication 
withdrawal [67]. 
Alternatively, replacement therapies using human embryonic stem cells 
(hESC) and induced pluripotent stem cells (iPSC) have shown potential with 
derived neurons surviving in vivo in animal trials [68], but are in the process of 
clinical application. 
Such stem-cell based therapies face inevitable safety concerns, as there is a 
danger of tumor formation due to an overgrowth or genetic abnormalities in the 
graft [69]. Moreover, creating patient-specific iPSCs by reprogramming somatic 
cells is highly cost-consuming [69]; thus, sufficient trials and investigations to 
ensure safety and affordability would be required. 
Recent research interests have been directed to the direct lineage 
reprogramming of glial cells to dopaminergic neurons, as it has benefits of no 
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Gene therapies 
 
Viral vector gene delivery 
 
Restoration of dopamine has been attempted with gene therapies, by using 
adeno-associated virus vectors (AAV) to deliver genes coding for dopamine 
biosynthetic enzymes - aromatic amine decarboxylase (AADC), tyrosine 
hydroxylase, and cyclohydrolase-1 - into the striatum [69]. Several phase I trials 
for the delivery of AADC via AAV into the putamen showed increased “on” time 
for PD patients and thus the safety of the intervention [71,72,73]. Moreover, the 
delivery of AADC, tyrosine hydroxylase, and cyclohydrolase-1 into the putamen 
using lentivirus vectors - which have a larger potential genetic cargo compared to 
AAV - resulted in a significant increase in Unified Parkinson Disease Rating 
Scale (UPDRS) motor scores [74]. 
Alternatively, gene encoding glutamic acid decarboxylase (GAD), an enzyme 
responsible for the synthesis of gamma-aminobutyric acid (GABA), has been 
delivered to the STN using AAV in the hope of reducing STN hyperactivity [75]. 
The AAV-GAD group showed significant improvement in the UPDRS motor 
scores compared to the sham group, with mild adverse events. 
 
Restorative gene therapies 
 
AAV has also been used in restorative gene therapies; glial cell line derived 
neurotrophic factor (GDNF), which is responsible for the differentiation and 
maintenance of dopaminergic neurons, has been delivered to the putamen using 
AAV under MRI-guided administration, resulting in an increased GDNF 
expression without clinical or radiographic toxicity [76]. However, phase II trial of 
AAV delivery of neurturin, a natural analogue of GDNF, has shown insignificant 
increase in UPDRS motor score compared to that of the sham group [77].  
 
 
Alpha-synuclein based therapies 
 
After the first identification of mutations in the SNCA gene coding for alpha-
synuclein as the first genetic cause of PD in 1997 [78], it was found that alpha-
synuclein was the main composition of Lewy bodies and Lewy neurites in PD 
[79]. Since then, various experimental approaches have been tested to reduce the 
neurotoxicity of alpha-synuclein aggregates. 
 
Reducing alpha-synuclein production 
 
One approach to the alpha-synuclein therapy is reducing the translation of the 
protein through RNA interference, where exogenous synthetic RNA molecules 
trigger the knockdown of the alpha-synuclein mRNA [80]. For instance, the 
introduction of a small-interfering RNA (siRNA) directed against alpha-synuclein 
in a mouse model led to the reduction of alpha-synuclein expression [80]; 
moreover, a similar study conducted in non-human primate models resulted in a 
40-50% reduction in alpha-synuclein expression. 
In an alternative perspective, the alpha-synuclein gene can be silenced to 
reduce the transcription of the mRNA. β2-adrenergic receptor agonist - namely 
clenbuterol - has been reported to reduce alpha-synuclein gene expression by 
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35%, and a potential association with a reduction of developing PD has been 
identified [81].  
A point of consideration in these methods is that the inhibition of alpha-
synuclein expression may lead to a loss of the protein’s normal physiological 
function, which is hypothesized to be related to a number of roles including the 
suppression of apoptosis [82], regulation of glucose levels [83] and dopamine 
production [84], chaperone activity [85], and antioxidation [86]. This is supported 
by studies that observed neurotoxicity and neurodegeneration in the SNc of 
alpha-synuclein silenced models [87]. 
 
Increasing alpha-synuclein clearance 
 
Immunotherapies aimed at degrading extracellular alpha-synuclein aggregates 
are currently being actively investigated in preclinical as well as clinical trials. In 
a phase I clinical trial of an immunotherapy vaccine containing alpha-synuclein-
mimicking peptides, the vaccine was found to trigger immune response against 
the peptide as well as extracellular alpha-synuclein without significant 
complication [88]. Moreover, anti-alpha-synuclein monoclonal antibodies were 
shown to reduce alpha-synuclein levels in healthy human subjects without 
adverse events and neurotoxicity [89], and are currently being tested against 
early PD patients in a phase II trial.  
In terms of intracellular alpha-synuclein, the lysosome-autophagy system that 
can clear alpha-synuclein aggregates via autophagy can be enhanced to reduce 
alpha-synuclein accumulation. This idea has been supported by the study 
showing that rapamycin, an agent that induces macroautophagy, is able to 
reverse alpha-synuclein accumulation [90]. Other autophagy enhancers such as 
trehalose and nortriptyline are currently being studied as potential subjects for 




Neuroprotective therapies are aimed at slowing or stopping disease 
progression. Of particular interest is exenatide, which is a glucagon-like peptide-1 
(GLP-1) receptor agonist typically used in the improvement of glycemic control 
in type 2 diabetes mellitus patients. Its ability to protect neurons from metabolic 
and oxidative stress has been demonstrated in rodent models of PD, created by 
6-hydroxydopamine (6-OHDA), lipopolysaccharide (LPS) [91], and MPTP [92]. 
Moreover, in a phase 2 clinical trial, PD patients that received subcutaneous 
administration of exenatide showed a slight improvement of symptoms during the 
“off” period; however, a relatively small sample size and short trial duration limit 
the study’s implications and thus would need further investigation [93]. 
In addition to the MAO-B inhibitors, NMDA glutamate receptors, 
neurotrophic factors, and exenatide, several agents are being investigated for 
their potential neuroprotective effects on PD. They include iron chelators (i.e. 
deferiprone) [94], calcium channel blockers (i.e. isradipine) [95], coenzyme Q10 
with antioxidative effects, antiapoptotic agents (i.e. inosine) [96], and nicotine. 
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Conclusion 
 
Since the 1817 introduction of PD by James Parkinson, significant strides 
have been made not only in the development of effective treatments, but also in 
the understanding of the potential mechanisms of the disease and the creation of 
models to test them. However, the exact etiology of the disease and a therapy 
that can reverse disease progression are yet to be determined. 
Existing treatments for PD are palliative in nature, focusing on the relief of 
dopaminergic motor symptoms and the simultaneous reduction of drug related 
complications such as dyskinesia and motor fluctuations. Such debilitating side 
effects and the resulting reduction of the efficacy of medicinal therapy in 
advanced PD indicate the pressing need for the development of a treatment of 
which the therapeutic effect can be persisted continuously. In this context, it is 
suggested that active research is required in the direction of elucidating the 
fundamental factors responsible for the pathogenesis of the disease, such as the 
dynamics of alpha-synuclein fibrillation and mitochondrial defects. This will 
ultimately lead to the creation of curative treatments addressing the cause of PD 
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